CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Merrion Pharmaceuticals Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Merrion Pharmaceuticals Plc
3200 Lake Drive
Citywest Business Campus, Dublin 24
Phone: +353 16423300p:+353 16423300 DUBLIN, 24  Ireland Fax: +353 16423301f:+353 16423301

This company is no longer actively traded on any major stock exchange.

Business Summary
Merrion Pharmaceuticals plc is an investment company, with a focus on the healthcare sector. The Company was engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection. The Company delivered oral pharmaceuticals by partnering with other pharmaceutical companies and using its GIPET technology. The Company intends to acquire companies or assets of companies operating in the healthcare sector. The Company focuses primarily on opportunities located in the United States and the United Kingdom. The Company's subsidiaries include Merrion Pharmaceuticals Holdings Limited, Merrion Pharmaceuticals Ireland Limited, Merrion Pharmaceuticals LLC, Merrion Research I Limited, Merrion Research II Limited and Merrion Research III Limited.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201512/31/2015Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Michael J.McKenna 12/24/2013 4/1/2004
Chief Executive Officer, Executive Director JohnFox 59 1/1/2014 1/1/2014
Non-Executive Director FintanMaher 4/1/2004 4/1/2004

General Information
Stock Exchange: ISE
Fax Number: +353 16423301


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023